# Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes

> **NCT04262479** · PHASE2 · COMPLETED · sponsor: **Norwegian University of Science and Technology** · enrollment: 14 (actual)

## Conditions studied

- Latent Autoimmune Diabetes in Adults

## Interventions

- **DRUG:** recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
- **DRUG:** Vitamin D

## Key facts

- **NCT ID:** NCT04262479
- **Lead sponsor:** Norwegian University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-02
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-05-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262479, "Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04262479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*